Surgical resection, in suitably selected patients, is the most effective treatment for colorectal liver metastases. In most series postoperative mortality is less than 4% and 5-year survival approaches 30% 1 . However, selection is of crucial importance and even on the most liberal criteria few patients' metastases are in fact suitable for surgical excision. By far the majority have disease which extends beyond surgical intervention or have comorbidity which makes the procedure untenable. The results of surgery depend upon an expert multidisciplinary team and surgical expertise, and survival rates will also depend greatly on the criteria for resection. This review article discusses novel concepts and techniques for dealing with unresectable colorectal liver metastases. It must be emphasized that optimum management requires input from many different specialties, with consideration of all options in the context of the patient's quality of life. The role of systemic chemotherapy is not speci®cally included in this review since the principle is established and patients are offered this treatment either as a solitary therapy or in combination with each of the three therapies discussed. Poon et al. 2 provide an up-to-date review of regimens for systemic chemotherapy in advanced disease 3 .
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NEOADJUVANT CHEMOTHERAPY
Attempts have been made to increase the resectability rate of patients with multiple or irresectable liver metastases. The hope is that, by downstaging of initially inoperable disease with chemotherapy, the patient becomes suitable for resection. There are no randomized trials of such an approach but several groups have reported evidence of survival improvement (Table 1 ). Other groups have utilized regional chemotherapy with the same objective and some of the results have been impressive ( Table 2) . Various chemotherapy regimens have been tried, and the combination of 5-¯uorouracil (5-FU), folinic acid and oxaliplatin is particularly encouraging 6 ; there is now a strong argument for testing of this regimen in a randomized trial.
After downstaging by neoadjuvant therapy, surgery can be carried out with low morbidity and mortality, although the liver may be more than usually friable and haemorrhagic in these circumstances 6±10 . In the large study by Bismuth et al. 6 , chemotherapy was achieved in an ambulatory setting with a time-dose programmed multichannel pump connected to a subcutaneously implanted venous port. The mean duration of chemotherapy before surgery was eight months. A further means to improve resectability rates is preoperative portal embolization. This technique is designed to induce a 40±60% increase in the volume of the non-embolized portion of the liver 11 , so that a greater proportion of the diseased liver can be removed without critical loss of liver function. Portal vein embolization is performed by percutaneous ultrasound guided puncture of a portal vein radical.
INTRAHEPATIC ARTERIAL CHEMOTHERAPY
Colorectal liver metastases derive a substantial proportion of their blood supply from the hepatic artery, and appreciation of this fact has led to the evolution of hepatic arterial chemotherapy to target metastases. The high ®rstpass ratio of 5-FU and¯uorodeoxyuridine through the liver leads to high hepatic drug concentrations with little systemic exposure 12 . Access to the hepatic circulation is gained via the gastroduodenal artery, through an incision similar to that for open cholecystectomy. (All patients require a preoperative angiogram to ensure that there are no vascular anomalies.) Prolonged infusions are used rather than bolus injection of drugs since 5-FU is cytotoxic in the S-phase of the cell cycleÐthus long infusions`catch' more susceptible cells.
Initial studies of this technique were hampered by technical dif®culties related to hepatic arterial catheter placement and maintenance. With implantable pumps and subcutaneous ports many of these have been circumvented. Several research groups have reported response rates of over 50%, with improvement in overall survival. The few randomized trials also indicate improved locoregional response rates, though survival differences are more doubtful (Table 3 ). In a meta-analysis of the ®ve studies comparing intra-arterial therapy with systemic therapy 18 , the overall locoregional liver response rate was 41% versus 14% and median survival was 16 months versus 12. Catheter-related dif®culties still arise. Port sepsis and occlusion can develop early although the median time to occlusion is 9±12 months. Chemical hepatitis and liver failure have been reported but should be rare.
THERMAL ABLATION
Thermal ablation requires introduction of the heat source directly into the tumour and is usually performed percutaneously with image guidanceÐcomputed tomography, ultrasound or magnetic resonance singly or in combination. Some procedures have been performed laparoscopically or at open laparotomy.
Laser
It is nearly 10 years since the ®rst reports of the use of laser energy to ablate liver metastases 19±21 . Both NdYAG and solid-state lasers are effective. Either bare tip laser ®bres, which act as a point source producing a sphere of necrosis, or diffuser ®bres are used 22, 23 . Important developments in laser technology include internal cooling of the applicator to prevent charring (which impedes tissue heating) and an increase in power deposition 24 .
Radiofrequency
Radiofrequency produces heating by ionic agitation. Initial electrodes were of low power (550 W) and were not internally cooled. The new systems have cooled tip electrodes and high-power generators (5200W); arrays of electrodes can be activated simultaneously 25, 26 . The two electrode designs now in use are a triple cluster (Radionics, Belgium), consisting of three parallel electrodes in triangular con®guration with 5 mm between them, and an umbrella design which opens out after introduction (Radiotherapeutics, USA).
Radiofrequency or laser?
From surgical data we know that successful treatment of liver metastases demands resection with a 1 cm margin of normal-appearing tissue. Of the two techniques, laser has the advantage of being magnetic resonance compatible, permitting direct MR monitoring. However, extensive ablation, and in particular ablation of a margin of normal liver, is easier to achieve with radiofrequency 27 (Figure 1 ), and this advantage is likely to be re¯ected in rates of recurrence adjacent to areas of thermal ablation. Another development has been the adoption of thermal ablation as an adjunctive technique to hepatic resection or cryoablation 28 .
Clinical results
The ef®cacy of radiofrequency has been validated in a small cohort of patients who subsequently underwent surgical resection: 8 of 9 showed complete ablation 29 31 . Our historical survival ®gures with laser showed a median survival of 33 months in patients with three or fewer metastases less than 5 cm in diameter 32 . Improvements in technology have permitted extension of the technique to patients with more widespread disease. More recent results show a median survival of 32 months and three-year survival of 39% in patients with fewer than ®ve metastases smaller than 5 cm and no extrahepatic disease 33 . We currently use cooled electrodes, arrays for larger lesions and a high-power generator.
CONCLUSION
Both laser and radiofrequency are effective for ablation of liver metastases, and advances in both technologies mean that larger volumes of tissue can be ablated 34 . The next step will be controlled trials of thermal ablation versus liver resection in operable metastases and of chemotherapy and ablation versus chemotherapy alone. 
